Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Amygdala Lesions Reduce Anxiety-like Behavior in a Human Benzodiazepine-Sensitive Approach-Avoidance Conflict Test.

Korn CW, Vunder J, Miró J, Fuentemilla L, Hurlemann R, Bach DR.

Biol Psychiatry. 2017 Oct 1;82(7):522-531. doi: 10.1016/j.biopsych.2017.01.018. Epub 2017 Feb 10.

2.

Long-Term Citalopram Treatment Alters the Stress Responses of the Cortical Dopamine and Noradrenaline Systems: the Role of Cortical 5-HT1A Receptors.

Kaneko F, Kawahara Y, Kishikawa Y, Hanada Y, Yamada M, Kakuma T, Kawahara H, Nishi A.

Int J Neuropsychopharmacol. 2016 Aug 12;19(8). pii: pyw026. doi: 10.1093/ijnp/pyw026. Print 2016 Aug.

3.

The crossroads of anxiety: distinct neurophysiological maps for different symptomatic groups.

Gerez M, Suárez E, Serrano C, Castanedo L, Tello A.

Neuropsychiatr Dis Treat. 2016 Jan 18;12:159-75. doi: 10.2147/NDT.S89651. eCollection 2016.

4.

Risk factors for excessive benzodiazepine use in a working age population: a nationwide 5-year survey in Norway.

Fride Tvete I, Bjørner T, Skomedal T.

Scand J Prim Health Care. 2015;33(4):252-9. doi: 10.3109/02813432.2015.1117282.

5.

Kava for the treatment of generalised anxiety disorder (K-GAD): study protocol for a randomised controlled trial.

Savage KM, Stough CK, Byrne GJ, Scholey A, Bousman C, Murphy J, Macdonald P, Suo C, Hughes M, Thomas S, Teschke R, Xing C, Sarris J.

Trials. 2015 Nov 2;16:493. doi: 10.1186/s13063-015-0986-5.

6.

Perinatal Generalized Anxiety Disorder: Assessment and Treatment.

Misri S, Abizadeh J, Sanders S, Swift E.

J Womens Health (Larchmt). 2015 Sep;24(9):762-70. doi: 10.1089/jwh.2014.5150. Epub 2015 Jun 30.

7.

The janus face of stress on reproduction: from health to disease.

Zelena D.

Int J Endocrinol. 2015;2015:458129. doi: 10.1155/2015/458129. Epub 2015 Apr 7. Review.

8.

Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders.

Singewald N, Schmuckermair C, Whittle N, Holmes A, Ressler KJ.

Pharmacol Ther. 2015 May;149:150-90. doi: 10.1016/j.pharmthera.2014.12.004. Epub 2014 Dec 27. Review.

9.

Efficacy and safety of duloxetine in the treatment of older adult patients with generalized anxiety disorder: a randomized, double-blind, placebo-controlled trial.

Alaka KJ, Noble W, Montejo A, Dueñas H, Munshi A, Strawn JR, Lenox-Smith A, Ahl J, Bidzan L, Dorn B, Ball S.

Int J Geriatr Psychiatry. 2014 Sep;29(9):978-86. doi: 10.1002/gps.4088. Epub 2014 Feb 20.

10.

Adequacy of treatment received by primary care patients with anxiety disorders.

Weisberg RB, Beard C, Moitra E, Dyck I, Keller MB.

Depress Anxiety. 2014 May;31(5):443-50. doi: 10.1002/da.22209. Epub 2013 Nov 4.

11.

50 years of hurdles and hope in anxiolytic drug discovery.

Griebel G, Holmes A.

Nat Rev Drug Discov. 2013 Sep;12(9):667-87. doi: 10.1038/nrd4075. Review.

12.

Potential antianxiety activity of Fumaria indica: A preclinical study.

Singh GK, Chauhan SK, Rai G, Chatterjee SS, Kumar V.

Pharmacogn Mag. 2013 Jan;9(33):14-22. doi: 10.4103/0973-1296.108129.

13.
14.

Complementary medicine, exercise, meditation, diet, and lifestyle modification for anxiety disorders: a review of current evidence.

Sarris J, Moylan S, Camfield DA, Pase MP, Mischoulon D, Berk M, Jacka FN, Schweitzer I.

Evid Based Complement Alternat Med. 2012;2012:809653. doi: 10.1155/2012/809653. Epub 2012 Aug 27.

15.

Exercise offers anxiolytic potential: a role for stress and brain noradrenergic-galaninergic mechanisms.

Sciolino NR, Holmes PV.

Neurosci Biobehav Rev. 2012 Oct;36(9):1965-84. doi: 10.1016/j.neubiorev.2012.06.005. Epub 2012 Jul 5. Review.

16.

Healthcare utilization and costs in patients beginning pharmacotherapy for generalized anxiety disorder: a retrospective cohort study.

Berger A, Edelsberg J, Bollu V, Alvir JM, Dugar A, Joshi AV, Oster G.

BMC Psychiatry. 2011 Dec 12;11:193. doi: 10.1186/1471-244X-11-193.

17.

Socially anxious primary care patients' attitudes toward cognitive bias modification (CBM): a qualitative study.

Beard C, Weisberg RB, Primack J.

Behav Cogn Psychother. 2012 Oct;40(5):618-33. doi: 10.1017/S1352465811000671. Epub 2011 Nov 30.

18.

The age of anxiety: role of animal models of anxiolytic action in drug discovery.

Cryan JF, Sweeney FF.

Br J Pharmacol. 2011 Oct;164(4):1129-61. doi: 10.1111/j.1476-5381.2011.01362.x. Review.

19.

Pregabalin influences insula and amygdala activation during anticipation of emotional images.

Aupperle RL, Ravindran L, Tankersley D, Flagan T, Stein NR, Simmons AN, Stein MB, Paulus MP.

Neuropsychopharmacology. 2011 Jun;36(7):1466-77. doi: 10.1038/npp.2011.32. Epub 2011 Mar 23.

20.

Cognitive bias modification for anxiety: current evidence and future directions.

Beard C.

Expert Rev Neurother. 2011 Feb;11(2):299-311. doi: 10.1586/ern.10.194. Review.

Supplemental Content

Support Center